NGM BIOPHARMACEUTICALS INC
ngmbio.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2023 10-K, filed Mar 11, 2024. Its latest SEC filing is a 15-12G from Apr 15, 2024.
10-K for FY2023, filed Mar 11, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Discovers and develops medicines for patients with cancer, liver and metabolic diseases, and retinal diseases.
10-K for FY2023, filed Mar 11, 2024
How Did They Make Money?
Partners pay NGM under collaboration agreements for compound license options and research work. Payments can include upfront fees, research-cost reimbursements, payments when development or regulatory milestones are met, and royalties on product sales; research services are paid as NGM performs them.
10-K for FY2023, filed Mar 11, 2024All of the Company’s revenue to date has been generated from its collaboration agreements, primarily its collaboration agreement with…View ↗
The transaction price in each arrangement is generally comprised of a non-refundable upfront fee and unconstrained variable consideration…View ↗
The Company’s collaboration agreements may include contingent payments related to specified development and regulatory milestones or…View ↗
$4.4M
-
10-K for FY2023, filed Mar 12, 2024
$4.4M ↗
Who Were Their Customers?
NGM works with collaboration partners, primarily Merck, under agreements covering compound license options and research and development services.
10-K for FY2023, filed Mar 11, 2024All of the Company’s revenue to date has been generated from its collaboration agreements, primarily its collaboration agreement with…View ↗
Did Revenues Turn Into Profits?
No. It lost $142.4M in FY2023.
10-K for FY2023, filed Mar 12, 2024
How Were They Changing?
-
Apr 5, 2024
Parent completed its acquisition of NGM Bio
NGM Bio became Parent’s wholly-owned subsidiary, and its shares ceased trading on Nasdaq.
Sources
8-K, filed Apr 5, 2024
Following the closing of the tender offer, Merger Sub merged with and into NGM Bio and all shares of NGM Bio common stock that had not been…View ↗
Shrank. Revenue fell 96% in 4 years, from $103.5M in FY2019 to $4.4M in FY2023, about 55% a year.
A narrower development focus
The earlier report describes a pipeline across liver and metabolic disease, retinal disease and cancer. The latest focuses development on an oncology antibody, a liver-disease candidate and a hyperemesis gravidarum candidate, while continuing discovery research.
10-K for FY2020, filed Mar 15, 2021 10-K for FY2023, filed Mar 11, 2024Our discovery engine supports our ability to span multiple therapeutic areas. Currently our diverse pipeline of six product candidates can…View ↗
A new focus for aldafermin
The earlier report describes aldafermin trials for non-alcoholic steatohepatitis. The latest report says the company plans further development of aldafermin for primary sclerosing cholangitis.
10-K for FY2020, filed Mar 15, 2021 10-K for FY2023, filed Mar 11, 2024Our most advanced product candidate is aldafermin, a proprietary engineered analog of the human hormone fibroblast growth factor 19, or…View ↗
A different use for a candidate
The earlier report describes an NGM candidate for cancer-related appetite loss and cancer; the latest report prioritizes a candidate for hyperemesis gravidarum.
10-K for FY2020, filed Mar 15, 2021 10-K for FY2023, filed Mar 11, 2024Our most advanced product candidate, aldafermin (formerly NGM282), is wholly-owned by us and is in Phase 2b development for the treatment…View ↗
completing a Phase 1 Part 1b dose escalation cohort of the ongoing Phase 1/2 trial evaluating NGM707 in combination with KEYTRUDA®…View ↗
Who Did They Compete With?
Competes with ImmunOs, Adanate, Merck, Concentra, Immune-Onc, Celldex Therapeutics, OncoResponse, Elpiscience Biopharmaceuticals USA, Bristol-Myers Squibb, Biond, Sanofi, Agenus, Dr. Falk Pharma, Hepagene Therapeutics, Cascade Pharmaceuticals, Orbsen Therapeutics, Chemomab Therapeutics, Curome Biosciences, Pliant, and Escient
10-K for FY2023, filed Mar 11, 2024We believe NGM707 is the most advanced candidate currently in clinical development targeting both ILT2 and ILT4. Other clinical stage…View ↗
Loading...
